Maverick BioMetals

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface platforms.

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant challenges of male infertility. We recognize the critical gap in male fertility treatment and are committed to helping people on their path to parenthood. Our innovative in-vitro spermatogenesis (IVS) technology is poised to transform the fertility landscape, offering new hope and innovative solutions to those struggling to conceive. Led by a team of world-renowned scientists and physicians, we are advancing research into clinical applications. Our mission is to make parenthood a reality for more families through ethical, scientifically advanced fertility solutions. Did you know? *1 in 8 couples struggle with infertility. *50% of in vitro fertilization (IVF) procedures fail. *50% of infertility is linked to men. *Male infertility treatment has been stagnant since 1992. Paterna is the first to develop a truly new treatment for male infertility since then. With a strong foundation in science and a commitment to innovation, Paterna BioSciences is uniquely positioned to lead the next generation of male fertility treatments. We are actively seeking funding to accelerate our clinical development and commercialization efforts, bringing our life-changing technology to families worldwide. We help make parenthood possible. Learn more at www.PaternaBio.com Contact us: info@paternabio.com A New Paradigm in Human Reproduction.

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new preservation solutions and technologies to provide the highest quality of service to organ procurement organizations and transplant centers. The U.S. based company, headquartered in Northbrook, Illinois, is a leading supplier of preservation solutions worldwide with a focus on innovation in organ preservation and machine perfusion. Through a strong focus on collaboration with surgeons and transplant professionals, it continues to explore emerging science and preservation technologies.

Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.

Cataract surgery is the single most common procedure performed in the United States annually. Despite technological advancements in both surgical instrumentation and intraocular lens design, approximately 50% of patients are still unable to see well without glasses after surgery. Omega Ophthalmics has developed a new, proprietary lens that will increase the number of “glasses free” post-surgery patients to over 90% by reducing the variables during surgery, revolutionizing a market that has not seen positive, disruptive change in over sixty years. Since the global intraocular lens market has steadily grown and is currently projected to reach $4.3 billion by 2017, the Omega Gemini Refractive Capsule is well-positioned to become the new standard lens for cataract surgery. The Omega Gemini Refractive Capsule is an investigational device and is not approved for use in the United States.

Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe conditions. Our strategy for product development involves using established technologies in innovative ways to target well-understood disease processes. We aim to simplify our research by incorporating successful elements of technology to create localized treatments that concentrate on proven molecules and pathways. Our current focus is on gene therapy for Rheumatology / Osteoarthritis, Endocrinology / Diabetes, and Neurology / Stroke.

Aureka Biotechnologies is a pioneering biotech firm dedicated to democratizing the pharmaceutical sector in order to conquer sickness.

InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and proprietary treatments using its Matrix BioHydrogel. The company's platform develops and manufactures implantable time release products composed of its proprietary tunable and bio-polymeric hydro-gel by using hard particulates in soft matrix, enabling patients to get relieve from peri-operative regional pain by a long-lasting and long-acting non-opiate painkiller.

LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.

Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore is dedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect.

BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems.